Neuroleptic Malignant Syndrome Associated with Metoclopropamide in a Patient with Metastatic Gastric Carcinoma
PDF

Case Report

Neuroleptic Malignant Syndrome Associated with Metoclopropamide in a Patient with Metastatic Gastric Carcinoma

Gazi Med J 2013;24(2):53-54 DOI: 10.12996/gmj.2013.14
, , , , , ,
PDF
Permissions

Abstract

Neuroleptic malignant syndrome (NMS) is a rare syndrome which can be fatal and characterized by hyperthermia, muscular rigidity, changes in consciousness, autonomic dysfunction, increased serum creatinine kinase and leukocytosis. We present a case with metastatic gastric cancer developed neuroleptic malignant syndrome after metoclopropamide treatment. Metoclopropamide-associated neuroleptic malignant syndrome is a rare life-threatening condition. It occurs due to blockade of dopamin receptors by metoclopropamid in brain and high cholinergic stimulation

Keywords: Neuroleptic malignant syndrome, metoclopropamide, dopamin receptor blocker